Oral Immunotherapy With Human Secretory Immunoglobulin A Improves Survival in the Hamster Model of Clostridioides difficile Infection

J Infect Dis. 2021 Oct 28;224(8):1394-1397. doi: 10.1093/infdis/jiab087.


Coadministration of human secretory IgA (sIgA) together with subtherapeutic vancomycin enhanced survival in the Clostridioides difficile infection (CDI) hamster model. Vancomycin (5 or 10 mg/kg × 5 days) plus healthy donor plasma sIgA/monomeric IgA (TID × 21 days) or hyperimmune sIgA/monomeric IgA (BID × 13 days) enhanced survival. Survival was improved compared to vancomycin alone, P = .018 and .039 by log-rank Mantel-Cox, for healthy and hyperimmune sIgA, respectively. Passive immunization with sIgA (recombinant human secretory component plus IgA dimer/polymer from pooled human plasma) can be administered orally and prevents death in a partially treated CDI hamster model.

Keywords: Clostridioides difficile infection; immunotherapy; secretory IgA.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Clostridioides difficile*
  • Clostridium Infections / therapy*
  • Cricetinae
  • Humans
  • Immunoglobulin A
  • Immunoglobulin A, Secretory / therapeutic use*
  • Immunologic Factors
  • Immunotherapy / methods*
  • Vancomycin / therapeutic use*


  • Anti-Bacterial Agents
  • Immunoglobulin A
  • Immunoglobulin A, Secretory
  • Immunologic Factors
  • Vancomycin